John Henderson
Long/short equity, growth, momentum, event-driven

Multi-Bagger Potential As iCAD Nears A Pivotal Inflection Point

We believe iCAD, Inc. (NASDAQ:ICAD), a provider of innovative cancer detection and targeted therapy solutions, has the potential to double over the next twelve months and triple by the end of 2015. Multiple near-term catalysts will accelerate iCAD's top-line growth and position the company to return to GAAP profitability in the next 2-3 quarters, potentially as early as Q4. Given that iCAD's stock is cheap by various valuation metrics, undiscovered, and under-owned, we feel strongly that shares have minimal downside and substantial upside into both year-end and also throughout both 2014 and 2015.

iCAD is reminiscent of CalAmp (NASDAQ:CAMP) circa 2012. We alluded to this in our first article on iCAD earlier this year when the...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details